Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Oncogenic RAS proteins were historically considered undruggable due to inaccessible binding sites.
• Early research identified isoprenylation for RAS membrane anchorage and signaling, but farnesyltransferase inhibitors failed clinically.
• Recent advances reveal complex RAS regulation, including maturation, trafficking, and plasma membrane interactions, offering new therapeutic targets.

Purpose of the Study:

• To review the current understanding of RAS membrane targeting.
• To highlight the development and outcomes of inhibitors targeting various steps of RAS regulation.
• To explore new therapeutic strategies against oncogenic RAS proteins.

Main Methods:

• Literature review of RAS biology and therapeutic targeting.
• Analysis of inhibitors targeting RAS maturation, trafficking, and membrane localization.
• Synthesis of current knowledge on RAS protein regulation and signaling.

Main Results:

• Multiple vulnerabilities in RAS regulation have been identified.
• Inhibitors targeting various steps of RAS protein lifecycle have been developed.
• Understanding RAS membrane targeting provides new avenues for anti-RAS therapy.

Conclusions:

• RAS proteins are druggable through targeting their complex regulatory pathways.
• Inhibitors disrupting RAS maturation, trafficking, and membrane localization show therapeutic promise.
• Continued research into RAS biology is crucial for developing effective cancer treatments.